Table 1.

Population characteristics

	Overall (n = 80)	SAVR (n = 40)	TAVR (n = 40)	p
Clinical characteristics
Age [year (median IQR)]	76.5 [70,83]	72 [63,75]	81 [74,88]	< 0.001
Blood pressure (mm Hg)
Male gender	52 (65)	28 (70)	24 (60)	0.48
Bicuspid aortic valve	16 (20)	13 (32.5)	3 (7.5)	0.012
Pre-AVR AS severity				1
Moderate	1 (1.2)	1 (2.5)	0
Severe	79 (98.8)	39 (97.5)	40 (100)
Clinical risk factors
Coronary artery disease	32 (40)	12 (30)	20 (50)	0.11
Hypertension	57 (71.2)	26 (65)	31 (77.5)	0.32
Hyperlipidemia	51 (63.7)	24 (60)	27 (67.5)	0.64
Diabetes mellitus	18 (22.5)	8 (20)	10 (25)	0.77
NYHA ≥ 2	68 (85)	29 (72.5)	39 (97.5)	0.005
Intraoperative data
Valve size (mm, median [IQR])	25 [23,26]	23 [23,25]	26 [23,29]	< 0.001
Edwards (Magna/Inspiris resilia; Sapien 3)		33 (82.5)	35 (87.5)
Medtronic (Mosaic Valve/Avalus; Core valve)		7 (17.5)	5 (12.5)
Mean gradient
Pre-AVR	40.5 [30.2,47]	38.8 [29.8,45.5]	41 [33.6,47.7]	0.33
post-AVR	6 [4, 9]	8 [5.5,11]	4 [3, 6]	< 0.001
Pulse pressure
Use of inotropes*	29 (36.2)	27 (67.5)	2 (5)	< 0.001
Use of vasopressors**	23 (29.1)	9 (23.1)	14 (35)	0.36

AVR Aortic valve replacement, IQR Inter-quartile range, NYHA New York Heart Failure Association, SAVR Surgical aortic valve replacement, TAVR Transcatheter aortic valve replacement

*Inotropes = epinephrine, milrinone, dobutamine infusions

**Vasopressors = vasopressin, norepinephrine, phenylephrine infusions